Exclusive: Neurizon Secures $80M Milestone Deal with Elanco for Revolutionary ALS Drug Development

Global licensing agreement accelerates ALS treatment development timeline. Deal includes $80M in potential milestones plus royalties. See strategic impact details.Read More